MCID: DBT004
MIFTS: 51

Diabetic Polyneuropathy

Categories: Endocrine diseases, Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

MalaCards integrated aliases for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 12 55 15
Diabetes Mellitus with Polyneuropathy 12
Polyneuropathy in Diabetes 12
Diabetic Polyneuropathies 73

Classifications:

ICD10: 33


Summaries for Diabetic Polyneuropathy

MalaCards based summary : Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to diabetes mellitus and microvascular complications of diabetes 5. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are Neural Stem Cell Differentiation Pathways and Lineage-specific Markers and Detoxification of Reactive Oxygen Species. The drugs Pregabalin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Diabetic Polyneuropathy

Diseases related to Diabetic Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 29.8 AGER AKR1B1 SOD2 VEGFA
2 microvascular complications of diabetes 5 29.5 AGER AKR1B1 VEGFA
3 neuropathy 29.3 NGF POLG TWNK
4 diabetic neuropathy 27.2 AKR1B1 NGF NTF3 SOD2 SOD3 VEGFA
5 polyneuropathy 10.9
6 diabetic cataract 10.5 AKR1B1 VEGFA
7 asbestosis 10.4 SOD2 SOD3
8 diabetic angiopathy 10.4 AGER SOD2
9 lens disease 10.3 AKR1B1 VEGFA
10 microvascular complications of diabetes 3 10.1 AGER AKR1B1
11 carpal tunnel syndrome 10.1
12 mononeuropathy of the median nerve, mild 10.1
13 ataxia neuropathy spectrum 10.1 POLG TWNK
14 maternally-inherited progressive external ophthalmoplegia 10.1 POLG TWNK
15 opiate dependence 10.0 NGF VEGFA
16 mitochondrial dna depletion syndrome 4a 10.0 POLG TWNK
17 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 10.0 POLG TWNK
18 autonomic neuropathy 10.0
19 hypoglycemic coma 10.0 NTF3 VEGFA
20 chronic progressive external ophthalmoplegia 9.9 POLG TWNK
21 autosomal dominant progressive external ophthalmoplegia 9.9 POLG TWNK
22 ocular motility disease 9.9 POLG TWNK
23 endotheliitis 9.8
24 3-methylglutaconic aciduria, type v 9.8 POLG TWNK
25 retinal vascular disease 9.8 AKR1B1 VEGFA
26 chronic inflammatory demyelinating polyneuropathy 9.8
27 ischemia 9.8
28 hyperglycemia 9.8
29 demyelinating polyneuropathy 9.8
30 peripheral nervous system disease 9.8
31 type i 9.8
32 chronic pain 9.8
33 myoclonic epilepsy associated with ragged-red fibers 9.7 POLG SOD2 TWNK
34 ocular dominance 9.7 NGF NTF3
35 mitochondrial disorders 9.7 POLG SOD2 TWNK
36 neuroblastoma 9.6
37 aging 9.6
38 polyglucosan body myopathy 1 with or without immunodeficiency 9.6
39 diabetic foot ulcers 9.6
40 mononeuropathy 9.6
41 tarsal tunnel syndrome 9.6
42 vestibular disease 9.6
43 retinitis 9.6
44 pancreatitis 9.6
45 neuronitis 9.6
46 autonomic dysfunction 9.6
47 postherpetic neuralgia 9.6
48 diabetic autonomic neuropathy 9.4 AKR1B1 NGF NTF3
49 sensory peripheral neuropathy 9.2 NGF NTF3

Comorbidity relations with Diabetic Polyneuropathy via Phenotypic Disease Network (PDN): (show all 33)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Bronchitis
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Cataract
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Kidney Disease Microvascular Complications of Diabetes 1
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Mononeuritis Multiplex Mononeuropathy of the Median Nerve, Mild
Neurogenic Arthropathy Neurogenic Bladder
Partial Third-Nerve Palsy Peripheral Vascular Disease
Respiratory Failure Tabes Dorsalis
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to Diabetic Polyneuropathy

Symptoms & Phenotypes for Diabetic Polyneuropathy

MGI Mouse Phenotypes related to Diabetic Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 AGER CYBA NGF NTF3 POLG SOD2
2 homeostasis/metabolism MP:0005376 9.97 AGER AKR1B1 CYBA NGF NTF3 POLG
3 behavior/neurological MP:0005386 9.95 AGER AKR1B1 CYBA NGF NTF3 SOD2
4 mortality/aging MP:0010768 9.86 AKR1B1 NGF NTF3 POLG SOD2 SOD3
5 muscle MP:0005369 9.63 AGER NGF NTF3 POLG SOD2 VEGFA
6 skeleton MP:0005390 9.43 AGER AKR1B1 CYBA POLG SOD3 VEGFA
7 vision/eye MP:0005391 9.1 SOD2 VEGFA AKR1B1 CYBA NGF NTF3

Drugs & Therapeutics for Diabetic Polyneuropathy

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Acetylcholine Approved Phase 4 51-84-3 187
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
6 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Asthmatic Agents Phase 4
16 Autonomic Agents Phase 4
17 Bronchodilator Agents Phase 4
18 Fibrinolytic Agents Phase 4
19 Neuroprotective Agents Phase 4
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Phosphodiesterase Inhibitors Phase 4
22 Platelet Aggregation Inhibitors Phase 4
23 Protective Agents Phase 4,Phase 3
24 Respiratory System Agents Phase 4
25 Vasodilator Agents Phase 4
26 abobotulinumtoxinA Phase 4
27 Botulinum Toxins Phase 4
28 Botulinum Toxins, Type A Phase 4
29 Cholinergic Agents Phase 4
30 Neuromuscular Agents Phase 4
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
32 onabotulinumtoxinA Phase 4
33 Antidepressive Agents Phase 4,Phase 2
34 Dopamine Agents Phase 4,Phase 2
35 Duloxetine Hydrochloride Phase 4,Phase 2
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
37 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 2
38 Analgesics, Opioid Phase 4,Phase 3,Phase 2
39 Narcotics Phase 4,Phase 3,Phase 2
40
Serotonin Investigational, Nutraceutical Phase 4,Phase 2 50-67-9 5202
41
gamma-Aminobutyric acid Approved, Investigational Phase 3,Not Applicable 56-12-2 119
42
Capsaicin Approved Phase 2, Phase 3 404-86-4 1548943
43
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
44
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
45
Oxycodone Approved, Illicit, Investigational Phase 3,Phase 2 76-42-6 5284603
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
47
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 59-43-8, 70-16-6 1130
48
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
49
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3 13422-55-4
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
2 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
3 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
4 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
5 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
6 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
7 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
8 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3 Thioctic Acid
9 Neuropathic Pain Management Completed NCT01263132 Phase 3 F0434;Gabapentin
10 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
11 TempTouch IR Thermometry & Diabetic Patient Self-Care Completed NCT00289497 Phase 2, Phase 3
12 A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy Completed NCT00455520 Phase 3 CG5503;placebo
13 A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN) Terminated NCT01063868 Phase 3 Tapentadol extended release (ER);Oxycodone controlled release (CR)
14 Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy Unknown status NCT01175928 Phase 1, Phase 2
15 Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy Unknown status NCT00043797 Phase 2 Lidorestat (IDD 676)
16 Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain Unknown status NCT02597257 Phase 2 Lidocaine HCl;Normal saline
17 The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study Completed NCT01622777 Phase 2 Rosuvastatin;Placebo
18 Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic Completed NCT00878293 Phase 2 GRT6005;MS Continus®;Placebo
19 Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy Completed NCT02129231 Phase 2 calcined magnesia;Ezetimibe/simvastatin;Rosuvastatin
20 Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Completed NCT01607684 Phase 2
21 Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy Completed NCT00307749 Phase 2 Placebo;MCC-257;MCC-257;MCC-257
22 A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Po Completed NCT00944697 Phase 2 Oxycodone Naloxone;Placebo tablets
23 Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy Completed NCT01347671 Phase 2 GRT6005;GRT6005;GRT6005;Matching Placebo
24 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Completed NCT01201317 Phase 2 AZD2423;AZD2423;Placebo
25 Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy Completed NCT01469559 Phase 2 Novolin Toronto insulin;Normal saline
26 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT01079325 Phase 2 SB-509
27 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00406458 Phase 2 SB-509
28 Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 Completed NCT00665145 Phase 2 SB-509;SB-509;Placebo;SB-509
29 Effect of C-Peptide on Diabetic Peripheral Neuropathy Completed NCT00278980 Phase 2 C-peptide
30 Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00476931 Phase 2
31 Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain Completed NCT00507936 Phase 2 ABT-894;ABT-894;ABT-894;placebo;Duloxetine
32 Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). Completed NCT00501202 Phase 2 placebo;RWJ-333369 (carisbamate)
33 Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
34 Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
35 A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
36 ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy Terminated NCT00508430 Phase 2 ASP8825;Placebo
37 A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy Terminated NCT01087203 Phase 2
38 Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy Terminated NCT00756041 Phase 2 TAK-128
39 Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy Unknown status NCT00282685 Phase 1
40 Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg Completed NCT02955472 Phase 1 GLA5PR GLARS-NF3 tablet 150mg;GLA5PR GLARS-NF1 tablet 150mg
41 Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg Completed NCT02952937 Phase 1 GLA5PR GLARS-NF3 tablet 300mg;GLA5PR GLARS-NF1 tablet 300mg
42 Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain Unknown status NCT01180608 Not Applicable
43 Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Unknown status NCT01465620 Not Applicable
44 Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy Unknown status NCT01718015
45 Nerve Decompression for Ulcer Recurrence Avoidance (DURA) Unknown status NCT01762085 Not Applicable
46 Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block Unknown status NCT02737527 Not Applicable 10 ml of 0.25% levobupivacaine injection for LSB
47 Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy Completed NCT00802022 Not Applicable
48 Peripheral Nerve Stimulation in Diabetic Patients Completed NCT01488474
49 Surgical Decompression for Diabetic Neuropathy in the Foot Completed NCT01006915 Not Applicable
50 A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy Completed NCT02107469 Not Applicable Sida cordifolia roots;Phyllanthus niruri;Sida cordifolia roots extract;Phyllanthus niruri extract

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

Anatomical Context for Diabetic Polyneuropathy

MalaCards organs/tissues related to Diabetic Polyneuropathy:

41
Spinal Cord, Testes, Endothelial, Skin, Bone, Pancreas, Skeletal Muscle

Publications for Diabetic Polyneuropathy

Articles related to Diabetic Polyneuropathy:

(show top 50) (show all 363)
# Title Authors Year
1
Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy? ( 29383511 )
2018
2
Difference in normal limit values of nerve conduction parameters between Westerner and Japanese people may need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device(NC-stat<sup>a98</sup>/DPNCheck<sup>a8c</sup>). ( 29430866 )
2018
3
A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. ( 29346515 )
2018
4
Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. ( 29487078 )
2018
5
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan. ( 29975462 )
2018
6
Long-Term Spinal Cord Stimulation Alleviates Mechanical Hypersensitivity and Increases Peripheral Cutaneous Blood Perfusion in Experimental Painful Diabetic Polyneuropathy. ( 29522270 )
2018
7
Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? ( 29063451 )
2018
8
Characterization of the Nile Grass Rat as a Unique Model for Type 2 Diabetic Polyneuropathy. ( 29718319 )
2018
9
The Availability of Quantitative Assessment of Pain Perception in Patients With Diabetic Polyneuropathy. ( 29961741 )
2018
10
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. ( 29728528 )
2018
11
A model of chronic diabetic polyneuropathy: benefits from intranasal insulin are modified by sex and RAGE deletion. ( 28223295 )
2017
12
Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: a role for CWC22. ( 28250049 )
2017
13
Diabetic Polyneuropathy and Risk of Falls: Fear of Falling and Other Factors. ( 29590728 )
2017
14
Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. ( 28179465 )
2017
15
Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. ( 28296226 )
2017
16
The Role of Oxidative Stress, Mitochondrial Function, and Autophagy in Diabetic Polyneuropathy. ( 29204450 )
2017
17
Oxytocin provides protection against diabetic polyneuropathy in rats. ( 27881053 )
2017
18
The impact of type 1 diabetes and diabetic polyneuropathy on muscle strength and fatigability. ( 28285381 )
2017
19
Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes. ( 28573145 )
2017
20
Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. ( 29913894 )
2017
21
NC-stat for the diagnosis of diabetic polyneuropathy. ( 28281855 )
2017
22
Assessment of diabetic polyneuropathy in Zanzibar: Comparison between traditional methods and an automated point-of-care nerve conduction device. ( 29204366 )
2017
23
Transplantation of dental pulp stem cells improves long-term diabetic polyneuropathy together with improvement of nerve morphometrical evaluation. ( 29237486 )
2017
24
Sensitive detection of hemodynamic failure during orthostatic stress in patients with diabetic polyneuropathy using a mini laser Doppler blood flowmeter. ( 27939526 )
2016
25
Molecular underpinnings of diabetic polyneuropathy. ( 27451278 )
2016
26
The Facilitative Effect of Transcranial Direct Current Stimulation on Visuospatial Working Memory in Patients with Diabetic Polyneuropathy: A Pre-post Sham-Controlled Study. ( 27733822 )
2016
27
Fiber loss in diabetic polyneuropathy. ( 27253717 )
2016
28
Predictors of improvement and progression of diabetic polyneuropathy following treatment with I+-lipoic acid for 4years in the NATHAN 1 trial. ( 26651260 )
2016
29
High Plasma Pentraxin 3 Levels in Diabetic Polyneuropathy Patients with Nociceptive Pain. ( 27212074 )
2016
30
Might genetics play a role in understanding and treating diabetic polyneuropathy? ( 28032668 )
2016
31
Physical activity and albuminuria were associated with painful diabetic polyneuropathy in type 2 diabetes in an ethnic Chinese population. ( 27592367 )
2016
32
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. ( 28058263 )
2016
33
A standardized clinical evaluation of phenotypic diversity in diabetic polyneuropathy. ( 27322439 )
2016
34
Abnormalities of retinal ganglion cell complex at optical coherence tomography in patients with type 2 diabetes: a sign of diabetic polyneuropathy, not retinopathy. ( 26809902 )
2016
35
Sonographic features of peripheral nerves at multiple sites in patients with diabetic polyneuropathy. ( 26782023 )
2016
36
Comparative analysis of the effects combined physical procedures and alpha-lipoic acid on the electroneurographic parameters of patients with distal sensorimotor diabetic polyneuropathy. ( 27065527 )
2016
37
Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. ( 27417167 )
2016
38
Overcoming barriers to diabetic polyneuropathy management in primary care. ( 27939169 )
2016
39
Independent Risk Factors for Positive and Negative Symptoms in Patients with Diabetic Polyneuropathy. ( 27337438 )
2016
40
Cardiovascular Autonomic Dysfunction Predicts Diabetic Foot Ulcers in Patients With Type 2 Diabetes Without Diabetic Polyneuropathy. ( 27015188 )
2016
41
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study. ( 26881251 )
2016
42
Is Stem Cell Transplantation Ready for Prime Time in Diabetic Polyneuropathy? ( 27485630 )
2016
43
Spinal cord stimulation in experimental chronic painful diabetic polyneuropathy: Delayed effect of High-frequency stimulation. ( 27891705 )
2016
44
DIAGNOSTICS ALGORITHM OF DIABETIC POLYNEUROPATHY IN PREDICTION OF CLINICAL COURSE. ( 26887136 )
2015
45
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy--authors' reply. ( 26067119 )
2015
46
Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and A/-opioid receptor agonism. ( 25697471 )
2015
47
Pathways in the diagnosis and management of diabetic polyneuropathy. ( 25899758 )
2015
48
Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. ( 25970541 )
2015
49
Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammation phenotypes and ameliorated diabetic polyneuropathy. ( 27181261 )
2015
50
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy. ( 26067117 )
2015

Variations for Diabetic Polyneuropathy

Expression for Diabetic Polyneuropathy

Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for Diabetic Polyneuropathy

Pathways related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.23 NGF NTF3 VEGFA
2
Show member pathways
10.87 CYBA SOD2 SOD3
3 10.29 CYBA SOD2 SOD3

GO Terms for Diabetic Polyneuropathy

Cellular components related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial nucleoid GO:0042645 8.62 POLG TWNK

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.88 AKR1B1 CYBA SOD2 SOD3
2 positive regulation of cell migration GO:0030335 9.73 NTF3 SOD2 VEGFA
3 negative regulation of neuron apoptotic process GO:0043524 9.67 NGF NTF3 SOD2
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.59 AKR1B1 CYBA
5 modulation of chemical synaptic transmission GO:0050804 9.58 NGF NTF3
6 positive chemotaxis GO:0050918 9.57 NTF3 VEGFA
7 regulation of neuron differentiation GO:0045664 9.55 NGF NTF3
8 peripheral nervous system development GO:0007422 9.54 NGF NTF3
9 cellular response to oxidative stress GO:0034599 9.54 CYBA SOD2 SOD3
10 positive regulation of p38MAPK cascade GO:1900745 9.52 AGER VEGFA
11 positive regulation of receptor internalization GO:0002092 9.51 NTF3 VEGFA
12 nerve development GO:0021675 9.48 NGF NTF3
13 locomotion GO:0040011 9.46 NGF NTF3
14 response to hypoxia GO:0001666 9.46 AGER CYBA SOD3 VEGFA
15 removal of superoxide radicals GO:0019430 9.43 SOD2 SOD3
16 cellular response to glucose stimulus GO:0071333 9.43 CYBA POLG TWNK
17 nerve growth factor signaling pathway GO:0038180 9.4 NGF NTF3
18 mitochondrial DNA replication GO:0006264 9.32 POLG TWNK
19 superoxide metabolic process GO:0006801 9.13 CYBA SOD2 SOD3
20 induction of positive chemotaxis GO:0050930 8.8 AGER NTF3 VEGFA

Molecular functions related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.56 AKR1B1 CYBA SOD2 SOD3
2 growth factor activity GO:0008083 9.33 NGF NTF3 VEGFA
3 chemoattractant activity GO:0042056 9.32 NTF3 VEGFA
4 heparin binding GO:0008201 9.13 AGER SOD3 VEGFA
5 superoxide dismutase activity GO:0004784 8.62 SOD2 SOD3

Sources for Diabetic Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....